{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": 2019
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with increased kinase activity, which is likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism involving increased kinase activity leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assays were used to assess the phosphorylation of MKKs by LRRK2 variants.",
          "judgment": "Yes",
          "reasoning": "Kinase assays effectively model the disease pathogenesis by measuring kinase activity."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wild-type LRRK2 and kinase dead LRRK2 K1906M were used as controls. Experiments were performed in triplicate.",
              "judgment": "Yes",
              "reasoning": "Both wild-type and kinase dead controls were used, and experiments were performed in triplicate."
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "Known pathogenic variants (G2019S, I2020T) and benign variant (R1441C) were used as controls.",
              "judgment": "Yes",
              "reasoning": "Known pathogenic and benign variants were used as controls."
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "Statistical significance was determined by ANOVA/Tukey’s post-hoc test.",
              "judgment": "Yes",
              "reasoning": "Robust statistical analyses were performed to determine significance."
            },
            {
              "step_name": "Sub-step 4c: Correlate OddsPath",
              "extracted_paper_info": "LRRK2 G2019S shows a 3–4-fold higher phosphorylation of MKK6 compared with wild-type LRRK2.",
              "judgment": "Yes",
              "reasoning": "The increased phosphorylation suggests a strong pathogenic effect."
            }
          ]
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The LRRK2 G2019S variant shows significantly increased kinase activity, correlating with pathogenic effects. Robust statistical analyses support this conclusion."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": 2020
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with increased kinase activity, which is likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism involving increased kinase activity leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assays were used to assess the phosphorylation of MKKs by LRRK2 variants.",
          "judgment": "Yes",
          "reasoning": "Kinase assays effectively model the disease pathogenesis by measuring kinase activity."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wild-type LRRK2 and kinase dead LRRK2 K1906M were used as controls. Experiments were performed in triplicate.",
              "judgment": "Yes",
              "reasoning": "Both wild-type and kinase dead controls were used, and experiments were performed in triplicate."
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "Known pathogenic variants (G2019S, I2020T) and benign variant (R1441C) were used as controls.",
              "judgment": "Yes",
              "reasoning": "Known pathogenic and benign variants were used as controls."
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "Statistical significance was determined by ANOVA/Tukey’s post-hoc test.",
              "judgment": "Yes",
              "reasoning": "Robust statistical analyses were performed to determine significance."
            },
            {
              "step_name": "Sub-step 4c: Correlate OddsPath",
              "extracted_paper_info": "LRRK2 I2020T shows a 1.5-fold higher phosphorylation of MKK6 compared with wild-type LRRK2.",
              "judgment": "Yes",
              "reasoning": "The increased phosphorylation suggests a moderate pathogenic effect."
            }
          ]
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The LRRK2 I2020T variant shows moderately increased kinase activity, correlating with pathogenic effects. Robust statistical analyses support this conclusion."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": 1441
        },
        "variant_string_id": "LRRK2 R1441C"
      },
      "functional_evidence_aim": "Benign",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations are associated with increased kinase activity, which is likely causative for PD-associated neurotoxicity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism involving increased kinase activity leading to neurotoxicity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vitro kinase assays were used to assess the phosphorylation of MKKs by LRRK2 variants.",
          "judgment": "Yes",
          "reasoning": "Kinase assays effectively model the disease pathogenesis by measuring kinase activity."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "sub_steps": [
            {
              "step_name": "Sub-step 3a: Basic Controls and Replicates",
              "extracted_paper_info": "Wild-type LRRK2 and kinase dead LRRK2 K1906M were used as controls. Experiments were performed in triplicate.",
              "judgment": "Yes",
              "reasoning": "Both wild-type and kinase dead controls were used, and experiments were performed in triplicate."
            },
            {
              "step_name": "Sub-step 3c: Variant Controls",
              "extracted_paper_info": "Known pathogenic variants (G2019S, I2020T) and benign variant (R1441C) were used as controls.",
              "judgment": "Yes",
              "reasoning": "Known pathogenic and benign variants were used as controls."
            }
          ]
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_steps": [
            {
              "step_name": "Sub-step 4a: Statistical Analyses",
              "extracted_paper_info": "Statistical significance was determined by ANOVA/Tukey’s post-hoc test.",
              "judgment": "Yes",
              "reasoning": "Robust statistical analyses were performed to determine significance."
            },
            {
              "step_name": "Sub-step 4c: Correlate OddsPath",
              "extracted_paper_info": "LRRK2 R1441C shows no significant alteration in kinase activity.",
              "judgment": "Yes",
              "reasoning": "The lack of significant alteration suggests a benign effect."
            }
          ]
        }
      ],
      "final_evidence_strength": {
        "type": "Benign",
        "strength": "BS3_supporting"
      },
      "overall_conclusion": "The LRRK2 R1441C variant shows no significant alteration in kinase activity, correlating with a benign effect. Robust statistical analyses support this conclusion."
    }
  ]
}